Case Report

Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male

Table 2

Demographics of previous and present cases of Guillain-Barré syndrome associated with COVID-19 in Japan.

CaseAgeSexClinical featureGBS onset from the onset of COVID-19GBS onset from COVID-19 recoveryGBS electrophysiological subtypeAnti-ganglioside antibodyCSF protein (mg/dL)Immunological treatment

Wada et al. [7]69MaleAbsence of cough reflex, muscle weakness, areflexiaNot describedNot describedNot describedAnti-Gal-C antibody202IVIg
Hirayama et al. [5]54FemaleMuscle weakness, numbness, and areflexia in the lower limb20Approximately 1 weekAxonal typeNegativeNormal levelNo treatment
Kakumoto et al. [6]22MaleMuscle weakness, hypesthesia, dysarthria, dysphagia, left-sided facial numbness, and dysautonomia166AIDPNegative307IVIg
Present case52MaleMuscle weakness, dysphagia, areflexia, hyperhidrosis101AIDPAnti-GM3 antibody55IVIg, IVMP

Abbreviations: GBS, Guillain–Barré syndrome; CSF, cerebrospinal fluid; AIDP, acute inflammatory demyelinating polyneuropathy; IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone.